BioCentury
ARTICLE | Strategy

Sweet Spot revisited

Genzyme, other biotech pioneers may go, but mid-tier biopharma is growing

February 21, 2011 8:00 AM UTC

Another biotechnology pioneer is being swept away by an innovation-starved big pharmaceutical company, the latest reflection of the bleak outlook of a biopharma industry blanketed by R&D failures, hostile regulators, unwilling payers and the flight of risk capital.

There is no money for innovation, and there is no model for building real, sustainable next-generation companies. M&A is the fate for all who brush with success...